Ending TB: the world’s oldest pandemic-Reference-Cited by-同舟云学术

Ending TB: the world’s oldest pandemic

Published:2021-03 Issue:3 Volume:24 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J. Intern. AIDS Soc.

Author:

Kim Peter S¹^ORCID,Swaminathan Soumya²

Affiliation:

1. Division of AIDS National Institute of Allergy and Infectious DiseasesNational Institutes of Health Bethesda MD USA

2. World Health Organization Geneva Switzerland

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25698

Reference23 articles.

1. Characterization of Mycobacterium tuberculosis Complex DNAs from Egyptian Mummies by Spoligotyping

2. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

3. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis

4. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

5. Payam Nahid and Susan Dorman.High‐dose rifapentine with or without moxifloxacin for shortening treatment of TB: TB Trials Consortium study 31/ACTG A5349 phase III clinical trial results. The 51st World Union Conference on Lung Health October 21 2020.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Readability of Patient-Facing Information of Antibiotics Used in the WHO Short 6-Month and 9-Month All Oral Treatment for Drug-Resistant Tuberculosis;Lung;2024-07-26

2. Universal Lineage-Independent Markers of Multidrug Resistance in Mycobacterium tuberculosis;Microorganisms;2024-06-30

3. Artemisinin derivatives as potential drug candidates against Mycobacterium tuberculosis : insights from molecular docking, MD simulations, PCA, MM/GBSA and ADMET analysis;Molecular Simulation;2024-05-02

4. Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses;iScience;2023-05

5. Mycobacterium tuberculosisdisease associates with higher HIV-1-specific antibody responses;2022-12-02